Xin Lang Cai Jing·2025-07-31 13:10Group 1: Artificial Intelligence Initiatives - The State Council approved the "Artificial Intelligence +" action plan to promote large-scale commercial applications of AI, leveraging China's complete industrial system and large market scale [1] - The National Development and Reform Commission emphasized the need to deepen the "Artificial Intelligence +" initiative and promote high-quality development of the low-altitude economy [2] - The National Medical Insurance Administration supports the clinical application and pricing of new technologies like brain-computer interfaces, establishing pricing for related medical services [2] Group 2: Corporate Developments - Tesla expanded its Robotaxi service to the California Bay Area, covering cities from San Francisco to San Jose [4] - Dongxin Co. clarified that its products are not used in large model computing clusters, indicating potential risks due to rapid stock price increases [5] - Dingtong Technology's major shareholder plans to transfer 3% of the company's shares due to personal funding needs [5] Group 3: Clinical Trials and Approvals - Yahui Pharmaceutical reported positive preliminary results from its Phase Ib clinical trial for APL-1401, aimed at treating moderate to severe ulcerative colitis [5] - Micron Biotech received FDA approval for a Phase I clinical trial of CS231295, a selective AuroraB inhibitor for treating advanced solid tumors [6] - ST Norate obtained drug registration certificates for two new products, indicating expansion in reproductive and mental health sectors [7] Group 4: Financing and Investments - "Zero Degree Robotics" completed two rounds of financing totaling over 100 million yuan, focusing on technology development and production acceleration [10] - Puliyan Medical completed nearly $50 million in Series C financing to enhance product development and market expansion [11]